Pfizer CEO Bourla Says Company Looking For 'Superior' Results from Weight-Loss Drugs

Great to see you. Thank you.

I think if we were preparing for this period of loss of exclusivity was 2638, we did significant acquisitions. One of them is obesity, as you said, but seeds it in oncology and nothing in migraine. And those this first one is performing extremely well. This year would be approximately $10 billion sales, growing double digit actually to less than 25 and 26. We continue growing at double digit. So I think after the 28 period least where we are going to be a top line growth story, we will have exponential growth, but we're building the industry.

I think investors most recent catalysts and this is a year of at least favorites in catalysts we are expecting $3 have stopped is that they are significant. Two of them actually will be innovation material. But for you are one of these there's ultra long 30 days. So those will come in the first half of this year. The other is the combination of the deal. We want to come this year, but there are many more in Rex Group, which is only myeloma. Myeloma, a drug. As a result of these successful doubles, the reputation of what we are going after the vaccine against the thief. Right. Thank you. Which is a very big disease. And there is no vaccines. Right. Right. That's the first one is Lyme disease. So there are very various items. And of course, we start a lot of phase three start. So investors, I think, are watching over. And right now families that has a very low multiple. I think we should start migrating towards the average multiple women exceeded the goal post our lives.

I think wanted this the monthly dose, and that's a very clear differentiation, but pretty significant from the this reform in patient experience, but also even know reduction and cost of goods and all of that. The second is a combination between army and you do what we are looking for superior results than the current solution. So those this combination not only will be a market, but hopefully you can deliver better weight loss, see more doctors and better tolerability, which are the two things but our the Achilles heel. So the GOP arms race and of course there is an oral advantage following. So it's a very complete, highly differentiated portfolio in the sense of a company that is very good in commercial activities, particularly when it comes to products, but they are very much consumer driven. I remind you why it is a product that was behaving very similar like the video, so like to watch.